Cardiff Oncology Analyst Ratings
Cardiff Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 479.71% | HC Wainwright & Co. | $13 → $12 | Maintains | Buy |
| 08/08/2023 | 528.02% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/09/2023 | 576.33% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 03/29/2023 | 624.64% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/07/2023 | 624.64% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 09/16/2022 | 576.33% | HC Wainwright & Co. | $22 → $14 | Maintains | Buy |
| 09/13/2022 | 141.55% | Piper Sandler | $7 → $5 | Maintains | Overweight |
| 08/29/2022 | 189.86% | Baird | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 962.8% | HC Wainwright & Co. | $25 → $22 | Maintains | Buy |
| 02/28/2022 | 1107.73% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 12/08/2021 | 817.87% | Baird | → $19 | Initiates Coverage On | → Outperform |
| 08/10/2021 | 1156.04% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 05/10/2021 | 1107.73% | HC Wainwright & Co. | $27 → $25 | Maintains | Buy |
| 10/22/2020 | 1204.35% | HC Wainwright & Co. | → $27 | Initiates Coverage On | → Buy |
| 10/08/2020 | 1107.73% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 09/18/2020 | 576.33% | Maxim Group | $6 → $14 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月11日 | 479.71% | HC Wainwright公司 | $13→$12 | 維護 | 買 |
| 2023/08/08 | 528.02% | HC Wainwright公司 | $14→$13 | 維護 | 買 |
| 05/09/2023 | 576.33% | HC Wainwright公司 | $15→$14 | 維護 | 買 |
| 03/29/2023 | 624.64% | HC Wainwright公司 | →$15 | 重申 | →購買 |
| 03/07/2023 | 624.64% | HC Wainwright公司 | $14→$15 | 維護 | 買 |
| 09/16/2022 | 576.33% | HC Wainwright公司 | $22→$14 | 維護 | 買 |
| 09/13/2022 | 141.55% | 派珀·桑德勒 | $7→$5 | 維護 | 超重 |
| 2022年08月29日 | 189.86% | 貝爾德 | $9→$6 | 維護 | 跑贏大盤 |
| 05/09/2022 | 962.8% | HC Wainwright公司 | $25→$22 | 維護 | 買 |
| 02/28/2022 | 1107.73% | HC Wainwright公司 | $26→$25 | 維護 | 買 |
| 12/08/2021 | 817.87% | 貝爾德 | →$19 | 開始承保 | →跑贏大盤 |
| 2021/08/10 | 1156.04% | HC Wainwright公司 | $25→$26 | 維護 | 買 |
| 2021/05/10 | 1107.73% | HC Wainwright公司 | $27→$25 | 維護 | 買 |
| 10/22/2020 | 1204.35% | HC Wainwright公司 | →$27 | 開始承保 | →購買 |
| 10/08/2020 | 1107.73% | 派珀·桑德勒 | →$25 | 開始承保 | →超重 |
| 09/18/2020 | 576.33% | Maxim集團 | $6→$14 | 維護 | 買 |
What is the target price for Cardiff Oncology (CRDF)?
卡迪夫腫瘤(CRDF)的目標價格是多少？
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $12.00 expecting CRDF to rise to within 12 months (a possible 479.71% upside). 8 analyst firms have reported ratings in the last year.
加的夫腫瘤公司(納斯達克代碼：CRDF)的最新目標價是由HC Wainwright&Co.於2023年8月11日報道的。這家分析公司將目標價定為12美元，預計CRDF將在12個月內上漲(可能上漲479.71%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
加的夫腫瘤學(CRDF)的最新分析師評級是什麼？
The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
加的夫腫瘤學公司(納斯達克代碼：CRDF)的最新分析師評級由HC Wainwright&Co.提供，加的夫腫瘤學公司維持買入評級。
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
加的夫腫瘤學(CRDF)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與加的夫腫瘤公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。卡迪夫腫瘤學的上一次評級是在2023年8月11日提交的，所以你應該預計下一次評級將在2024年8月11日左右提供。
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
分析師對加的夫腫瘤學(CRDF)的評級正確嗎？
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $13.00 to $12.00. The current price Cardiff Oncology (CRDF) is trading at is $2.07, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的加的夫腫瘤學(CRDF)評級保持不變，目標價在13.00美元至12.00美元之間。卡迪夫腫瘤公司目前的交易價格為2.07美元，超出了分析師的預測範圍。